Theravance-GSK's Relvar is backed for approval in EU for asthma, COPD

09/20/2013 | Reuters

The European Medicines Agency endorsed the approval of GlaxoSmithKline and Theravance's Relvar as a treatment for asthma and chronic obstructive pulmonary disease. The inhaled drug, marketed as Breo in the U.S., is a combination of corticosteroid and a long-acting beta-agonist. A final decision is expected in the next quarter.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC